site map | search | contact | disclaimer  
  December 01, 2008  
QLT INC.
OUR BUSINESS IS SCIENCE. OUR PRODUCT IS LIFE.


QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies.

Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to create products such as Visudyne® and Eligard® and future product opportunities.


CURRENT CLINICAL TRIALS
All Trials


Employee Login
QLT To Repurchase Up to US$50 Million of Common Shares QLT To Repurchase Up to US$50 Million of Common Shares
December 01, 2008
QLT Announces Third Quarter Results for 2008 QLT Announces Third Quarter Results for 2008
October 28, 2008
QLT Announces Encouraging Phase II Data From Core Study of Punctal Plug Drug Delivery System QLT Announces Encouraging Phase II Data From Core Study of Punctal Plug Drug Delivery System
October 28, 2008
More press releases in our News Center...

Rodman & Renshaw 10th Annual Healthcare Conference
QLT is scheduled to present on Wednesday, November 12, 2008 at 11:10 a.m. ET in New York City. Click here to listen to the presentation.


Q3 2008 Earnings Conference Call
QLT will broadcast its Q3 2008 Earnings Conference Call on Tuesday, October 28 at 8:30 am ET. Click here to listen to the webcast.


UBS 2008 Global Life Sciences Conference
QLT presented on Thursday, September 25, 2008 at 12:30 p.m. ET in New York City. Click here to listen to a replay of the presentation.







Copyright © 2000 - 2008 QLT Inc. All rights reserved. See legal terms for use of site and Privacy Policy.